Medicare Part D Premiums Will Decline
CMS announced that the average basic premium for Medicare Part D will decline in 2018. The average premium will be $33.50 per month, down $1.20 from the currently average premium of $34.70. The premium decline will occur despite the fact that spending for Part D continues to grow faster than spending for other parts of Medicare. This growth in spending has largely been driven by high-cost specialty drugs.
Molina Will Exit Utah and Wisconsin Exchanges
Facing losses for a second quarter, Molina Healthcare is reducing its involvement in the Affordable Care Act (ACA)’s health exchanges. The Wall Street Journal reported that Molina will leave the exchanges in Utah and Wisconsin and reduce involvement in the Washington state exchange. For the exchanges it is remaining in, Molina will increase premiums by an average of 55%. Molina’s move leaves 1 Wisconsin county with no exchange insurer.
Scientists Successfully Edit Genes in a Human Embryo
For the first time, scientists have edited the genes in a human embryo to repair a disease-causing mutation. The research represents a hope that babies could be protected from hereditary conditions, but also renews ethical concerns, reported The New York Times. The scientists were able to repair dozens of embryos and fix a mutation that causes a common, and often fatal, heart condition. The hypothesis is that babies born from the repaired embryos would not only not develop the disease themselves, but they would not pass the disease on to descendants.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
2 Commerce Drive
Cranbury, NJ 08512